Pfizer, BioNTech propose expanding COVID-19 vaccine trial to 44,000 volunteers

Drugmakers racing to develop a safe and effective coronavirus vaccine pledged in July to ensure their larger clinical trials would include diverse sets of volunteers. "Diversity in clinical trials is a priority for Pfizer and is critical given that COVID-19 disproportionately impacts communities of color in the U.S.," Pfizer's Chief Business Officer John Young said in a U.S. congressional hearing in July.